Sonoma Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q2 Fiscal Year 2027 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Growth Quarterly19.5MTarget: Continued double-digit expansion driven by U.S. and European markets
U.S. Revenue Growth Rate Quarterly117.0%Target: Sustain triple-digit or high double-digit growth via expanded OTC distribution
Gross Profit Margin Quarterly38.0%Target: Maintain or improve above 38% through manufacturing efficiencies
EBITDA Loss Reduction Quarterly-2.1MTarget: Narrowing toward break-even by fiscal year 2028
Watch Items
- Nasdaq Listing ComplianceTrigger: Stock price consistently below $1.00 or failure to meet minimum market value rulesAction: Monitor share price closely; evaluate potential reverse stock splits or corporate actions to maintain listing status
- Dilution Risk and Option OverhangTrigger: Further public offerings or high outstanding option poolsAction: Assess capital structure and cash runway to minimize dilutive impact on existing shareholders
- Consumer-Market OTC ExpansionTrigger: Rising SG&A and marketing expenses without proportional revenue growthAction: Review commercial channel efficiency and distribution partner performance (e.g., CVS, Walmart, Medline)
Research as of 20 Jun 2026